Tezepelumab Study for Adults With Moderate to Very Severe COPD
Tests tezepelumab against placebo in adults with moderate to very severe COPD.
Plain-language title generated from the registry record
Registry title: A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Key facts
- Where
- Adairsville, Anderson, Ann Arbor, Atlanta, Baltimore, Bay Pines, Birmingham, Boerne, Bowling Green, Boynton Beach, Charlotte, Clearwater, Colchester, Columbia, Concord, Cordele, Cullman, Decatur, El Paso, Evanston, Evansville, Everett, Fayetteville, Fleming Island, Fort Eisenhower, Gaffney, Grants Pass, Hannibal, Hendersonville, Hinsdale, Horsham, Houston, Indianapolis, Inglewood, Jacksonville, Kansas City, Kenosha, Knoxville, Lebanon, Leesburg, Lewisville, Little River, Los Angeles, Margate, McKinney, Mesquite, Miami, Miami Lakes, Minneapolis, New Britain, Ocala, Oklahoma City, Owensboro, Palmetto Bay, Palo Alto, Phoenix, Pittsburgh, Potomac, Rapid City, Redding, Rosedale, San Antonio, San Diego, Savannah, Sayre, Scottsdale, Spartanburg, Springfield, Staten Island, Syracuse, The Bronx, Tulsa, Union, Williamsburg, Wilmington, and Winter Park, United StatesSee the 76 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT06878261, who can take part
Where in United States
- AdairsvilleAdairsville, United StatesNo longer taking part
- AndersonAnderson, United StatesTaking people
- Ann ArborAnn Arbor, United StatesTaking people
- AtlantaAtlanta, United StatesTaking people
- BaltimoreBaltimore, United StatesTaking people
- Bay PinesBay Pines, United StatesTaking people
- BirminghamBirmingham, United StatesNot yet recruiting
- BoerneBoerne, United StatesTaking people
- Bowling GreenBowling Green, United StatesTaking people
- Boynton BeachBoynton Beach, United StatesTaking people
- CharlotteCharlotte, United StatesTaking people
- ClearwaterClearwater, United StatesNo longer taking part
- ColchesterColchester, United StatesTaking people
- ColumbiaColumbia, United StatesTaking people
- ConcordConcord, United StatesNot yet recruiting
- CordeleCordele, United StatesTaking people
- CullmanCullman, United StatesTaking people
- DecaturDecatur, United StatesTaking people
- El PasoEl Paso, United StatesTaking people
- EvanstonEvanston, United StatesTaking people
- EvansvilleEvansville, United StatesTaking people
- EverettEverett, United StatesTaking people
- FayettevilleFayetteville, United StatesNo longer taking part
- Fleming IslandFleming Island, United StatesNo longer taking part
- Fort EisenhowerFort Eisenhower, United StatesNo longer taking part
- GaffneyGaffney, United StatesTaking people
- Grants PassGrants Pass, United StatesNo longer taking part
- HannibalHannibal, United StatesTaking people
- HendersonvilleHendersonville, United StatesNot yet recruiting
- HinsdaleHinsdale, United StatesNot yet recruiting
- HorshamHorsham, United StatesNot yet recruiting
- HoustonHouston, United StatesTaking people
- IndianapolisIndianapolis, United StatesTaking people
- InglewoodInglewood, United StatesNo longer taking part
- JacksonvilleJacksonville, United StatesTaking people
- Kansas CityKansas City, United StatesTaking people
- KenoshaKenosha, United StatesNot yet recruiting
- KnoxvilleKnoxville, United StatesTaking people
- LebanonLebanon, United StatesNot yet recruiting
- LeesburgLeesburg, United StatesTaking people
- LewisvilleLewisville, United StatesTaking people
- Little RiverLittle River, United StatesNo longer taking part
- Los AngelesLos Angeles, United StatesNo longer taking part
- MargateMargate, United StatesNo longer taking part
- McKinneyMcKinney, United StatesTaking people
- MesquiteMesquite, United StatesTaking people
- MiamiMiami, United StatesTaking people
- Miami LakesMiami Lakes, United StatesNo longer taking part
- MinneapolisMinneapolis, United StatesTaking people
- New BritainNew Britain, United StatesTaking people
- OcalaOcala, United StatesTaking people
- Oklahoma CityOklahoma City, United StatesTaking people
- OwensboroOwensboro, United StatesTaking people
- Palmetto BayPalmetto Bay, United StatesNo longer taking part
- Palo AltoPalo Alto, United StatesTaking people
- PhoenixPhoenix, United StatesTaking people
- PittsburghPittsburgh, United StatesNot yet recruiting
- PotomacPotomac, United StatesTaking people
- Rapid CityRapid City, United StatesTaking people
- ReddingRedding, United StatesTaking people
- RosedaleRosedale, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- San DiegoSan Diego, United StatesNo longer taking part
- SavannahSavannah, United StatesTaking people
- SayreSayre, United StatesTaking people
- ScottsdaleScottsdale, United StatesTaking people
- SpartanburgSpartanburg, United StatesTaking people
- SpringfieldSpringfield, United StatesNot yet recruiting
- Staten IslandStaten Island, United StatesTaking people
- SyracuseSyracuse, United StatesTaking people
- The BronxThe Bronx, United StatesTaking people
- TulsaTulsa, United StatesTaking people
- UnionUnion, United StatesTaking people
- WilliamsburgWilliamsburg, United StatesTaking people
- WilmingtonWilmington, United StatesTaking people
- Winter ParkWinter Park, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06878261EU 2024-517457-27-00
- Record updated
- 9 October 2026
- Original description
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)Read full original descriptionShow less
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Inclusion: ≥40 to ≤80 years old; COPD diagnosis ≥1 year,; Post-BD FEV1 ≥ 20% and ≤ 70% PN, FEV1/FVC <0.70 at screening; Triple (ICS+LABA+LAMA) or dual inhaled COPD therapy, if triple therapy is considered not appropriate, ≥3 consecutive months prior to V1; ≥2 moderate or ≥1 severe COPD exacerbations in the prior year; At least 1 of 2 moderate exacerbations must require the use of systemic corticosteroids. At least one of the previous exacerbations should be confirmed to have occurred while the participant was on triple or dual inhaled maintenance therapy; EOS ≥ 150 cells/μL during screening; CAT ≥15 at screening; Former or current smokers ≥10 pack-years.
Exclusion: Tuberculosis requiring treatment within 12 months prior V2; Malignancies current or past; Concomitant therapies:; Macrolides (less than 6 months); Systemic immuno-suppressive, -modulating medications; Clin. important pulmonary disease or radiological findings suggestive of a respiratory disease other than COPD; Any unstable disorder that can impact participants safety or study outcomes; Asthma, incl. pediatric, or ACOS; LTOT >4.0 L/min or O2 saturation <89% despite LTOT.